公开(公告)号：BR112022009259A2

公开(公告)日：2022-08-02

申请号：BR112022009259

申请日：2020-11-16

Applicant: ACADEMIA SINICA

Inventor： HAN-CHUNG WU ,  HAO-NIEN CHEN

IPC: C07K16/18 ,  A61P35/00 ,  A61P43/00 ,  C07K16/30

Abstract: MÉTODOS PARA TRATAR, INIBIR OU ELIMINAR UM CÂNCER EM UM INDIVÍDUO. A presente invenção refere-se ao uso terapêutico de anticorpos anti-EpCAM. Também é fornecida uma terapia imunológica combinada de um anticorpo anti-EpCAM e um inibidor de ponto de checagem imunológico de PD-L1.

公开(公告)号：BR112017022205A2

公开(公告)日：2018-08-28

申请号：BR112017022205

申请日：2016-04-12

Applicant: ACADEMIA SINICA

Inventor： CHIUNG-YI CHIU ,  HAN-CHUNG WU ,  I-JU LIU ,  RUEI-MIN LU ,  YU-LING CHANG

IPC: C07K16/28

Abstract: a presente invenção refere-se a um anticorpo isolado ou um fragmento de ligação a antígeno do mesmo tendo uma afinidade de ligação específica a um epí-topo localizado dentro do domínio 1 ou domínio 3 do receptor de fator de crescimen-to endotelial vascular 2 humano (vegfr2; seq id no: 74). o epítopo dentro do domínio 3 do vegfr2 é localizado entre os resíduos de amino ácido 250 e 270 de seq id no: 74. o uso do anticorpo ou fragmento de ligação a antígeno do mesmo na fabricação de um medicamento para inibir o desenvolvimento de tumor, a angio-gênese do tumor, e/ou para induzir a citotoxicidade das células de câncer em um indivíduo em necessidade do mesmo é também descrito. também é descrito um mé-todo de detectar a presença de vegfr2 em uma célula endotelial de tumor vascu-lar ou uma célula de câncer em uma amostra biológica.

公开(公告)号：AU2010215974A1

公开(公告)日：2011-09-01

申请号：AU2010215974

申请日：2010-02-19

Applicant: ACADEMIA SINICA ,  LIANG CHI MING

Inventor： HAN-CHUNG WU ,  CHIEN-YU CHIU

IPC: C07K7/08 ,  A61K38/10 ,  A61P35/00 ,  C12N15/11

Abstract: Cancer-targeting peptides and uses thereof in cancer therapy.

公开(公告)号：US20200031875A1

公开(公告)日：2020-01-30

申请号：US16597850

申请日：2019-10-10

Applicant: ACADEMIA SINICA

Inventor： HAN-CHUNG WU ,  CHUNG-TAO TANG

IPC: C07K14/005 ,  A61K39/12 ,  C07K16/10 ,  G01N33/569 ,  A61K39/39 ,  C12N7/00

Abstract: Isolated mutant dengue virus E protein variants are disclosed. The variant comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 1 and has one or more amino acid residue substitutions at position corresponding to Asn8 (N8), Arg9 (R9), Val12 (V 12) and/or Glu13 (E13). The variant may comprise an amino acid sequence that is at least 90% identical to the SEQ ID NO: 1 and lack an infection-enhancing antibody-binding motif comprising the amino acid sequence of SEQ ID NO: 28 at domain I. An isolated nucleic acid sequence encoding the variant, a plasmid expressing the variant, a plasmid expressing a virus-like particle comprising the variant, a DNA vaccine, and a method of detecting the presence of a dengue virus in a biological sample are also disclosed.

公开(公告)号：US20130084298A1

公开(公告)日：2013-04-04

申请号：US13644311

申请日：2012-10-04

Applicant: Academia Sinica

Inventor： HAN-CHUNG WU ,  Kuo-Hua Tung

IPC: A61K39/395 ,  C07K16/46 ,  G01N21/76 ,  A61P35/00 ,  G01N33/574 ,  C07K16/28 ,  C12N9/96

CPC classification number: C07K16/18 ,  C07K16/303 ,  C07K2317/73

Abstract: A purified monoclonal antibody, or an. antigen-binding portion thereof, which specifically binds to human clathrin heavy chain (CHC) is disclosed. The antibody, or antigen-binding portion, thereof, exhibits at least one, two, three, four, five, six, seven, or all eight of the following properties: (a) specifically binds to pancreatic adenocarcinoma cells; (b) binding to the cell surface and cytosol of cancer cells and tumor blood vessels; (c) internalized by CHC-expressing cells; (d) inhibiting tumor growth, invasion ability, migration, and angiogenesis; (e) inducing apoptosis in cancer cells and human umbilical vein endothelial cells; (f) inhibiting tumor growth and tumor blood vessels in pancreatic cancer in vivo; (g) suppressing epidermal growth factor, transferrin, and VEGF internalizations by cancer cells; and (h) suppressing hypoxia-inducible factor-1α expression and vascular endothelial growth factor secretion. Methods for inhibiting tumor cell growth and/or angiogenesis, and detecting cancer in a subject is also disclosed.

Abstract translation: 纯化的单克隆抗体，或 公开了与人网格蛋白重链（CHC）特异性结合的抗原结合部分。 抗体或其抗原结合部分显示出以下性质中的至少一种，二种，三种，四种，五种，六种，七种或全部八种：（a）特异性结合胰腺腺癌细胞; （b）结合癌细胞和肿瘤血管的细胞表面和细胞溶质; （c）通过表达CHC的细胞内化; （d）抑制肿瘤生长，侵袭能力，迁移和血管生成; （e）诱导癌细胞和人脐静脉内皮细胞凋亡; （f）体内抑制胰腺癌肿瘤生长和肿瘤血管; （g）抑制癌细胞的表皮生长因子，转铁蛋白和VEGF内化; 和（h）抑制低氧诱导因子-1α表达和血管内皮生长因子分泌。 还公开了抑制肿瘤细胞生长和/或血管发生以及检测受试者中的癌症的方法。